|
Feb 20
|
Inventiva and Hepalys Pharma, Inc. announce the initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 trial
|
|
Feb 10
|
Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
|